Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer [Yahoo! Finance]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Yahoo! Finance
Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily pretreated population that company executives said has historically seen minimal benefit from standard options. Late-line colorectal cancer data and patient population Founder and CEO Mark Lappe said the company's newly released results involved 45 evaluable patients with advanced or metastatic unresectable colorectal cancer (CRC). According to Lappe, 70% of patients received ozekibart plus FOLFIRI as fourth-line therapy and 30% received it as third-line therapy. He added that 80% of patients were already refractory to irinotecan. ? GE Vernova Beats Earnings by 790% as Data Center Demand Explodes Lappe contrasted the study outcomes with historical expectations in this setting, describing the standard of care as having an objective response rate (ORR) of “almost zero” and a median progression-free survival (PFS) of “only two to three months.” In the ozekibart combination cohort, Lappe reported an OR
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences (INBX) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue [Seeking Alpha]Seeking Alpha
- T-Mobile reportedly in merger talks, Adobe's $25B stock buyback [Yahoo! Finance Canada]Yahoo! Finance Canada
- Inhibrx cancer drug reportedly drawing interest of Merck and rivals [Seeking Alpha]Seeking Alpha
INBX
Earnings
- 8/13/25 - Beat
INBX
Sec Filings
- 4/27/26 - Form 4
- 4/23/26 - Form ARS
- 4/23/26 - Form DEF
- INBX's page on the SEC website